Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVanderbilt University Medical Center

About this trial

The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections.

This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant.

Reduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID

Eligibility criteria

Qualifiers

Prior RT-PCR-confirmed COVID-19 infection.

Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms.

Disqualifiers

Heart Disease: Myocardial Infarction, angina, heart failure

History of stroke, or transient ischemic attack

Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)

Uncontrolled hypertension defined as persistent blood pressure >140/90.

Trial design

Treatments tested in this trial

  • Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls
  • Levels of inflammatory cytokine ( IL-6) in controls
  • Effect on inflammation after chronic PNS stimulation

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Vanderbilt University Medical Center

Lead sponsor

American Heart Association

Collaborator